327,624
Participants
Start Date
April 15, 2019
Primary Completion Date
December 10, 2021
Study Completion Date
December 10, 2021
Subjects treated with Empagliflozin or any Sodium-glucose cotransporter-2 (SGLT-2) inhibitor
Empagliflozin or any Sodium-glucose cotransporter-2 (SGLT-2) inhibitor
Subjects treated with Dipeptidyl peptidase-4 (DPP-4) inhibitor
Dipeptidyl peptidase-4 (DPP-4) inhibitor
Taiwan Society for Pharmacoeconomics and Outcome Research (TaSPOR), Taipei
Steno Diabetes Center Copenhagen, Department of Clinical Epidemiology, Gentofte Municipality
Ajou University Hospital, Suwon
Instituto de Investigación Sanitaria INCLIVA, Valencia
University of Ulm, Institute for Epidemiology and medical biometry, Ulm
Maccabi Healthcare Services, Tel Aviv
Helsinki University Hospital, Helsinki
Gifu University, Gifu
Oslo University Hospital, Department of Clinical Lipidology, Oslo
Oslo University Hospital, Department of Cardiology, Oslo
TFS Trial Form Support International AB, Lund
Quantify Research AB, Stockholm
Leicester Real World Evidence Unit, Leicester general Hospital, Leicester
Lead Sponsor
Boehringer Ingelheim
INDUSTRY